桂木 真司 (カツラギ シンジ)

KATSURAGI Shinji

写真a

所属

医学部 医学科 発達泌尿生殖医学講座産婦人科学分野

職名

教授

外部リンク

関連SDGs


 

論文 【 表示 / 非表示

  • Maternal Death Due to Pulmonary Arterial Hypertension ― A Nationwide Survey in Japan ―

    Aoki-Kamiya C., Katsuragi S., Shiina Y., Hasegawa J., Yoshimatsu J., Nakai A., Ishiwata I., Sekizawa A., Ikeda T.

    Circulation Journal   89 ( 1 )   77 - 82   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Circulation Journal  

    Background: With advances in treatment, the prognosis for pregnancies complicated by pulmonary arterial hypertension (PAH) has been improving. However, PAH-related maternal mortality remains high compared with that due to other cardiovascular diseases. The specifics of PAH-related maternal deaths under advanced medical standards are not well understood. Methods and Results: We used the maternal death registration system established by the Japan Association of Obstetricians and Gynecologists and reviewed 6 PAH-related maternal deaths from 2010 to 2022. All women were initially diagnosed with PAH during pregnancy or immediately after childbirth. The diagnosis of PAH tended to be delayed because symptoms were not reported to healthcare providers and/or a different disease was diagnosed. Cardiogenic shock occurred antepartum in 1 woman and during delivery or within 7 days after delivery in the other 5 women. Four women were resuscitated and started on extracorporeal membrane oxygenation. Pulmonary vasodilators were initiated in 4 women, with a median duration of 8 days from PAH diagnosis to starting medication. Right heart failure was the most common cause of maternal death, with a median duration of 16 days from PAH diagnosis to maternal death. Conclusions: All PAH-related maternal deaths occurred in women who were diagnosed with PAH after pregnancy. Diagnosing PAH and initiating pulmonary vasodilators takes considerable time, highlighting the importance of early diagnosis and early treatment.

    DOI: 10.1253/circj.CJ-24-0602

    Scopus

    PubMed

    CiNii Research

  • Tachycardia-Induced Cardiomyopathy Following Prolonged Ritodrine Infusion During Pregnancy: A Case Report.

    Nakao M, Izawa M, Takamisawa I, Horiuchi C, Ohmori A, Katsuragi S

    Cureus   16 ( 12 )   e76465   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.7759/cureus.76465

    PubMed

  • Out-of-pocket fertility preservation expenses: data from a Japanese nationwide multicenter survey

    Ono M., Takai Y., Harada M., Horie A., Dai Y., Kikuchi E., Miyachi M., Yamamoto T., Fujii N., Kajiyama H., Manabe A., Yasuoka T., Katsuragi S., Mekaru K., Maezawa T., Horage Y., Kataoka S., Nakayama R., Nakajima T.E., Kimura F., Shimizu C., Sugimoto K., Takae S., Yumura Y., Nishi H., Furui T., Morishige K.I., Watanabe C., Osuga Y., Suzuki N.

    International Journal of Clinical Oncology   29 ( 12 )   1959 - 1966   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    Background: The expenses related to fertility preservation or subsequent assisted reproductive treatments are significant for adolescents and young adult patients in Japan’s current healthcare system. With fertility preservation becoming more widespread in developed countries, it is expected that these costs will be covered by insurance or subsidies. It is critical for patients, healthcare providers, and the government to know the costs that patients will be responsible for. In Japan, the costs of fertility preservation and subsequent assisted reproductive technology are not covered by insurance, but patients can apply for subsidies from the local and central governments if certain conditions are met. Presently, the above-mentioned costs, as well as the amount paid by the patient, vary by facility. Therefore, it is essential to ensure patients’ continued access to necessary medical care despite the associated costs. Methods: In this study, questionnaires were mailed to 186 certified fertility preservation facilities in Japan to assess patients who had undergone fertility preservation or assisted reproduction. The questionnaires were sent between October 27, 2023 and March 31, 2024, with 140 of the 186 facilities responding (response rate: 75.3%). Results: Our findings show that approximately one-third of the costs was borne by the patients. Conclusion: Given these circumstances, sustainable pricing and insurance coverage are necessary for both patients and facilities.

    DOI: 10.1007/s10147-024-02614-z

    Scopus

    PubMed

  • Infection route associated with invasive group A streptococcal toxic shock syndrome in maternal deaths: Nationwide analysis of maternal mortalities in Japan

    Hasegawa J., Sekizawa A., Tanaka H., Katsuragi S., Tanaka K., Nakata M., Hayata E., Murakoshi T., Ishiwata I., Ikeda T.

    International Journal of Infectious Diseases   146   2024年9月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Infectious Diseases  

    Objectives: To clarify the infection route in maternal death due to invasive group A streptococcal (GAS) infection and toxic shock syndrome (TSS). Methods: A retrospective study was conducted on maternal deaths due to GAS-TSS in Japan between January 2010 and March 2024. The final causal diagnosis of maternal death and the infection routes of GAS were analysed using medical records, laboratory data and autopsy findings. Results: Among the 616 maternal deaths during the study period, 48 (8%) involved infectious diseases. The most common infection was invasive GAS (56%, n = 27), 21 (78%) and six cases occurred during the antepartum and puerperium periods, respectively. In the GAS-TSS group, 71% (15/21) infections were originated the upper respiratory tract. However, in the puerperium cases, 67% (4/6) were infected from the genital tract. In addition, no maternal deaths due to GAS-TSS were reported during the COVID-19 pandemic period in Japan from 2020 to 2023. Conclusion: Most antepartum GAS infections were from the upper respiratory tract. They may be reduced by preventive measures, including frequent disinfection, wearing masks and isolation from persons at high risk of carrying GAS, such as symptomatic children. On the other hand, GAS-TSS during puerperium infection via the genital tract.

    DOI: 10.1016/j.ijid.2024.107154

    Scopus

  • Relationship between maternal mortality and ritodrine hydrochloride as a tocolytic agent in Japan

    Nakamura M., Sekizawa A., Hasegawa J., Nakata M., Katsuragi S., Tanaka H., Murakoshi T., Kanayama N., Ishiwata I., Ikeda T.

    The journal of obstetrics and gynaecology research   50 ( 7 )   1111 - 1117   2024年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:The journal of obstetrics and gynaecology research  

    AIM: In Japan, unlike Western countries, tocolytic agents are administered in long-term protocols to treat threatened preterm labor. Evaluating the side effects of this practice is crucial. We examined whether ritodrine hydrochloride had been administered in cases of maternal death, aiming to investigate any relationship between ritodrine administration and maternal death. METHODS: This retrospective cohort study used reports of maternal deaths from multiple institutions in Japan between 2010 and 2020. Data on the reported cases were retrospectively analyzed, and data on the route of administration, administered dose, and clinical findings, including causes of maternal death, were extracted. The amount of tocolytic agents was compared between maternal deaths with ritodrine administration and those without. RESULTS: A total of 390 maternal deaths were reported to the Maternal Death Exploratory Committee in Japan during the study period. Ritodrine hydrochloride was administered in 32 of these cases. The frequencies (n) and median doses (range) of oral or intravenous ritodrine hydrochloride were 34.4% (11) and 945 (5-2100) mg and 84.4% (27) and 4032 (50-18 680) mg, respectively. Frequencies of perinatal cardiomyopathy, cerebral hemorrhage, diabetic ketoacidosis, and pulmonary edema as causes of maternal death were significantly higher with ritodrine administration than without it. CONCLUSIONS: Our results suggest a relationship between long-term administration of ritodrine hydrochloride and an increased risk of maternal death due to perinatal cardiomyopathy, cerebral hemorrhage, diabetic ketoacidosis, and pulmonary edema. In cases where ritodrine should be administered to prevent preterm labor, careful management and monitoring of maternal symptoms are required.

    DOI: 10.1111/jog.15951

    Scopus

全件表示 >>

書籍等出版物 【 表示 / 非表示

  • 胎児発育不全 = Fetal growth restriction

    池田 智明, 金山 尚裕, 関沢 明彦

    中外医学社  2018年 

     詳細を見る

    記述言語:日本語

    CiNii Books

  • 妊娠

    福井 トシ子(看護師、助産師、保健師), 竹田 省

    メディカ出版  2016年 

     詳細を見る

    記述言語:日本語

    CiNii Books

  • 産褥

    福井 トシ子(看護師、助産師、保健師), 竹田 省

    メディカ出版  2016年 

     詳細を見る

    記述言語:日本語

    CiNii Books

MISC 【 表示 / 非表示

  • Retraction notice to “Maternal blood concentration of tadalafil in pregnancy: Comparison of pregnant and non-pregnant women” [Taiwan J Obstet Gynecol 61 (2022) 230–233, (S1028455922000092), (10.1016/j.tjog.2022.02.009)]

    Enomoto N., Tanaka H., Maki S., Takakura S., Tanaka K., Katsuragi S., Ikeda T.

    Taiwanese Journal of Obstetrics and Gynecology   62 ( 6 )   2023年11月

     詳細を見る

    掲載種別:速報,短報,研究ノート等(学術雑誌)   出版者・発行元:Taiwanese Journal of Obstetrics and Gynecology  

    This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal). This article has been retracted at the request of the Editors. As the result of the submission of a correspondence article discussing concerns with the current study [1], the journal was made aware of allegations that some of the data presented in this article appeared to be identical to data presented in a previous publication by some of the same authors as in the present work [2]. Upon further investigation and assessment of the article, the journal found multiple instances of data in the current article that indeed appear to be duplicated. Specifically, Table 1 (Clinical parameters of the participants), Table 2 (Estimated tadalafil pharmacokinetic parameters in pregnant and non-pregnant women), and Figure 1 (Average concentration–time profiles of tadalafil and unbound tadalafil in pregnant and non-pregnant women) appear to have been reproduced from the previous publication without appropriate citation [2]. Additionally, reexamination of the article by the Editors has led them to conclude firstly that the side effects evaluated by the authors were overly subjective, and secondly that the authors failed to show the outcomes of fetuses in their study, but nonetheless claimed safety in the use of tadalafil in pregnant women, with both points raising questions about the reliability of the study's conclusions. The authors were contacted for comment but did not provide an explanation for the concerns listed above. The degree of redundant publication detailed above represents a misuse of the scientific publishing system. This, in addition to concerns regarding the reliability of the article's conclusions, has led to the decision to retract the article. The scientific community takes a very strong view on this matter and apologies are offered to readers of the journal that this was not detected during the submission process.

    DOI: 10.1016/j.tjog.2023.10.001

    Scopus

  • 妊娠高血圧症候群に関連した死亡の削減に向けて

    桂木真司

    周産期医学   2023年3月

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • もやもや病・脳動静脈奇形

    桂木真司

    ペリネイタルケア   2023年1月

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • 妊娠中の巨大子宮筋腫合併-核出術を行わない

    桂木真司

    周産期医学   2022年12月

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • 多胎妊娠の基礎知識 娩出時期と分娩管理

    桂木真司

    周産期医学   2022年9月

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

全件表示 >>

講演・口頭発表等 【 表示 / 非表示

  • 妊娠初期の高血圧管理 妊産婦とメンタルヘルス

    桂木真司

    令和5年度宮崎県産婦人科病医院従事者研修会 第27回ひむかセミナー 

     詳細を見る

    開催年月日: 2024年3月2日 - 2024年3月3日

    会議種別:口頭発表(招待・特別)  

  • HELLP症候群と非典型溶結性尿毒症症候群

    桂木真司

    宮崎aHUSセミナー 

     詳細を見る

    開催年月日: 2024年2月29日

    会議種別:口頭発表(招待・特別)  

  • 肺動脈性肺高血圧症と妊娠・出産

    桂木真司

    74th ACHD NIGHT 

     詳細を見る

    開催年月日: 2024年2月16日

    会議種別:口頭発表(招待・特別)  

  • 内科の先生に伝えたい妊産婦の管理

    桂木真司

    都城市北諸県郡医師会内科医会学術講演会 

     詳細を見る

    開催年月日: 2024年2月13日

    会議種別:口頭発表(招待・特別)  

  • 妊娠高血圧症候群による脳卒中の予防とアスピリン療法による次回妊娠の予防効果

    桂木真司

    日本周産期・新生児医学会第42回周産期学シンポジウム 

     詳細を見る

    開催年月日: 2024年1月26日 - 2024年1月27日

    会議種別:口頭発表(招待・特別)  

全件表示 >>

科研費(文科省・学振・厚労省)獲得実績 【 表示 / 非表示

  • 胎児期の低栄養環境による行動異常の発症とその早期診断に有効なマーカーに関する研究

    研究課題/領域番号:24K14793  2024年04月 - 2027年03月

    独立行政法人日本学術振興会  科学研究費基金  基盤研究(C)

     詳細を見る

    担当区分:研究代表者 

  • 小児・AYA 世代のがん患者等に対する妊孕性温存療法のエビデンス 確立を目指した研究―安全性と有効性の創出を目指して

    研究課題/領域番号:24EA2001  2024年04月 - 2026年03月

    厚生労働省  厚生科研  がん対策推進総合研究事業

     詳細を見る

    担当区分:研究分担者 

  • インド地下水汚染地域における妊娠、出産および小児の発育・発達に関する研究

    研究課題/領域番号:20KK0222  2020年10月 - 2025年03月

    独立行政法人日本学術振興会  科学研究費基金  国際共同研究加速基金(国際共同研究強化(B))

     詳細を見る

    担当区分:研究分担者 

  • 安心・安全な分娩を支援するtailor-made型の子宮頸管開大予測モデルの開発

    研究課題/領域番号:20K10831  2020年04月 - 2024年03月

    独立行政法人日本学術振興会  科学研究費補助金  基盤研究(C)

     詳細を見る

    担当区分:研究分担者 

共同研究実施実績 【 表示 / 非表示

  • 産後うつとエクオール産生能に関する探索研究

    2023年01月 - 2026年03月

    株式会社ヘルスケアシステムズ  国内共同研究 

     詳細を見る

    担当区分:研究代表者  共同研究区分:国内共同研究

寄附金・講座・研究部門 【 表示 / 非表示

  • 発達泌尿生殖医学講座産婦人科学分野研究奨学金

    寄附者名称:医療法人益治論会産婦人科いきめの杜クリニック 2024年03月

  • 発達泌尿生殖医学講座産婦人科学分野研究奨学金

    寄附者名称:医療法人社団育生会 2024年03月

  • 発達泌尿生殖医学講座産婦人科学分野研究奨学金

    寄附者名称:愛泉会日南病院 2024年03月

  • 発達泌尿生殖医学講座産婦人科学分野研究奨学金

    寄附者名称:ゆげレディスクリニック 2024年03月

  • 発達泌尿生殖医学講座産婦人科学分野研究奨学金

    寄附者名称:医療法人仁徳会渡辺産婦人科 2024年03月

全件表示 >>

研究・技術シーズ 【 表示 / 非表示